The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
55
Oral, tablet
Oral, tablet
Bishan Hospital of Chongqing
Chongqing, China
Frequency of treatment emergent adverse events
Time frame: From enrollment to end of follow-up visit, up to approximately 1 week
Plasma PK of Alpha-0261 after single dose
Maximum Plasma Concentration (Cmax)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
Plasma PK of Alpha-0261 after single dose
Elimination half life (T 1/2)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
Plasma PK of Alpha-0261 after single dose
Area Under the Concentration-time Curve (AUC)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
Plasma PK of Alpha-0261 after single dose
Time to Reach The Maximum Plasma Concentration (Tmax)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
Plasma PK of Alpha-0261 after single dose
Apparent Systemic Clearance (CL/F)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
Plasma PK of Alpha-0261 after single dose
Apparent Volume of Distribution (Vz/F)
Time frame: From enrollment to end of treatment period, up to approximately 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.